

# Juli M Bollinger

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/885638/publications.pdf>

Version: 2024-02-01

20  
papers

329  
citations

933264

10  
h-index

839398

18  
g-index

21  
all docs

21  
docs citations

21  
times ranked

613  
citing authors

#	ARTICLE	IF	CITATIONS
1	Public preferences regarding informed consent models for participation in population-based genomic research. <i>Genetics in Medicine</i> , 2014, 16, 11-18.	1.1	74
2	Patients'™ Attitudes toward the Donation of Biological Materials for the Derivation of Induced Pluripotent Stem Cells. <i>Cell Stem Cell</i> , 2014, 14, 9-12.	5.2	33
3	Choices for return of primary and secondary genomic research results of 790 members of families with Mendelian disease. <i>European Journal of Human Genetics</i> , 2017, 25, 530-537.	1.4	31
4	Development of the clinical next-generation sequencing industry in a shifting policy climate. <i>Nature Biotechnology</i> , 2014, 32, 980-982.	9.4	25
5	Patients' views concerning research on medical practices: Implications for consent. <i>AJOB Empirical Bioethics</i> , 2016, 7, 76-91.	0.8	23
6	Patients' perspectives on the derivation and use of organoids. <i>Stem Cell Reports</i> , 2021, 16, 1874-1883.	2.3	23
7	Enrolling Genomics Research Participants through a Clinical Setting: the Impact of Existing Clinical Relationships on Informed Consent and Expectations for Return of Research Results. <i>Journal of Genetic Counseling</i> , 2018, 27, 263-273.	0.9	19
8	Ethics and Collateral Findings in Pragmatic Clinical Trials. <i>American Journal of Bioethics</i> , 2020, 20, 6-18.	0.5	16
9	Barriers to clinical adoption of next-generation sequencing: a policy Delphi panel's solutions. <i>Personalized Medicine</i> , 2017, 14, 339-354.	0.8	15
10	Physicians'™ perspectives regarding pragmatic clinical trials. <i>Journal of Comparative Effectiveness Research</i> , 2016, 5, 499-506.	0.6	12
11	Risk perception before and after presymptomatic genetic testing for Huntington's disease: Not always what one might expect. <i>Molecular Genetics &amp; Genomic Medicine</i> , 2018, 6, 1140-1147.	0.6	10
12	Perceptions, motivations, and concerns about living organ donation among people living with HIV. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2018, 30, 1595-1599.	0.6	10
13	Patients'™ Views About the Disclosure of Collateral Findings in Pragmatic Clinical Trials: a Focus Group Study. <i>Journal of General Internal Medicine</i> , 2020, 35, 3436-3442.	1.3	7
14	Whether, when, and how to communicate genetic risk to minors: "I wanted more information but I think they were scared I couldn't handle it". <i>Journal of Genetic Counseling</i> , 2021, 30, 237-245.	0.9	7
15	Family Communication Patterns and Challenges of Huntington's™ Disease Risk, the Decision to Pursue Presymptomatic Testing, and Test Results. <i>Journal of Huntington's Disease</i> , 2020, 9, 265-274.	0.9	6
16	Developing context-specific next-generation sequencing policy. <i>Nature Biotechnology</i> , 2016, 34, 466-470.	9.4	5
17	Stakeholder perspectives regarding pragmatic clinical trial collateral findings. <i>Learning Health Systems</i> , 2020, 5, e10245.	1.1	5
18	Patients'™ Reactions to Letters Communicating Collateral Findings of Pragmatic Clinical Trials: a National Web-Based Survey. <i>Journal of General Internal Medicine</i> , 2022, 37, 1658-1664.	1.3	4

#	ARTICLE	IF	CITATIONS
19	Early experiences of independent advocates for potential HIV+ recipients of HIV+ donor organ transplants. <i>Clinical Transplantation</i> , 2019, 33, e13617.	0.8	3
20	Identification and management of pragmatic clinical trial collateral findings: A current understanding and directions for future research. <i>Healthcare</i> , 2021, 9, 100586.	0.6	1